GC Wellbeing·JW Pharmaceutical Rally [K-bio Pulse]

[Seungkwon Kim, Edaily Reporter] South Korea‘s pharma and biotech sector saw notable volatility on Aug. 13, driven by growth themes in obesity/medical aesthetics, hair loss, and immuno-oncology.

GCWellbeing surged about 17% on positive China Phase 3 data for its fat-dissolving injectable RZL-012. JWPharmaceutical rose roughly 11% on hopes for expanded hair-loss drug reimbursement. Genexine gained about 16% on renewed attention to its DNA vaccine platform and the resolution of an international arbitration dispute. Each rally reflected a distinct growth story rather than near-term earnings gains.

GC Wellbeing Stock Price

GC Wellbeing, China Phase 3 Win Validates One-to-Two-Dose Fat Reduction

GC Wellbeing closed up about 17% at 10,750 won after partner Raziel Therapeutics reported that RZL-012 met key efficacy and safety endpoints in a Chinese Phase 3 trial. The pivotal study enrolled 480 adults with submental fullness, run jointly by Raziel and Fosun Pharma affiliate JuveStar. RZL-012 met both primary and secondary endpoints at day 84 after a single treatment, with a response rate over 30 percentage points above placebo. Fosun and Raziel plan to file for approval with China’s NMPA by year-end and are pursuing trials to expand into the abdomen and thighs.

RZL-012 destroys targeted fat cells and is designed to work in just one or two injections, versus multiple sessions for existing products. GC Wellbeing licensed the domestic rights and made a strategic equity investment in Raziel in June.

A company official said, “This result confirms RZL-012‘s commercial potential. We will build a differentiated portfolio linking obesity care and medical aesthetics around this asset.”

The China success doesn’t guarantee a domestic approval timeline — Korean regulatory strategy and pricing still need to be worked out, making the local launch schedule the real test of long-term value.

JW Pharmaceutical Stock Price

JW Pharmaceutical, Hair-Loss Reimbursement Hopes Fuel Rally

JW Pharmaceutical closed up about 11% at 3,430 won, as hair-loss treatment emerges as the next growth category after obesity drugs and reports circulate that the government is reviewing expanded insurance coverage. Neither the scope nor timing has been confirmed, however, so some of the optimism may be running ahead of fundamentals.

The company‘s lineup spans oral drugs Monad Tab (finasteride) and Dutamoa Tab (dutasteride), topical minoxidil Mydil, and licensed Rogaine Foam, backed by a clinic-focused sales network in dermatology and urology. It has also added hair-care products via Galderma Korea and Pierre Fabre, and is co-developing a topical treatment, AD-303.

Group synergy is another factor: affiliate JW Central recently licensed a twice-monthly GLP-1 obesity drug from China’s Gan & Lee for $85 million and is developing its own hair-loss candidate, JW0061 — with JW Central handling hospital sales and global licensing while JW Pharmaceutical co-markets through clinics, a model already used for cholesterol drug Livalo.

A JW Central official said co-marketing arrangements would expand “once JW Central‘s new drugs are commercialized.”

Genexine, 16% Rally on Renewed Focus on $200M Arbitration Win

Genexine closed up about 16% at 3,260 won, with no fresh disclosure but renewed attention to its decisive ICC arbitration win against U.S.-based Ichor Medical Systems over the electroporation device used in its cervical cancer DNA vaccine candidate GX-188E. Ichor had alleged unauthorized use of its TriGrid device and sought up to $145.6 million in damages; the tribunal dismissed all claims and ordered Ichor to cover about 2.2 billion won of Genexine’s legal costs. On Aug. 31, Genexine petitioned the U.S. District Court for the Southern District of California to confirm and enforce the award.

Analysts note that resolving the legal overhang is separate from restoring enterprise value, which still hinges on clinical and commercialization progress. One industry source said the rally “reflects resolution of legal uncertainty and demand for a re-rating of the technology assets, but whether it holds depends on actual business results — investors should stay cautious.”